Roberto B.
- Country
- Italy
- Department
- Oncologia Medica
Research Overview
- Evaluation of BI 770371 and Pembrolizumab, With or Without Cetuximab, Versus Pembrolizumab Monotherapy in Head and Neck Squamous Cell Carcinoma Patients
- Phase 2 Randomized Trial of Durvalumab Followed by Chemotherapy Versus Chemotherapy Followed by Durvalumab in Elderly Patients with Advanced NSCLC
- Efficacy and Safety Evaluation of Luveltamab Tazevibulin Versus Investigator's Choice Chemotherapy in Relapsed Platinum-Resistant Epithelial Ovarian Cancer Expressing FOLR1
Data & Insights
Has run more than one trial at 161 of 363 partner sites.
Specializations
Gynecologic Oncology
Specializes in treating advanced ovarian cancer, fallopian tube cancer, and peritoneal cancers. Has particular focus on therapeutic approaches for both BRCA wild-type and recurrent cases.
- Maintenance therapy strategies
- Secondary cytoreductive surgery outcomes
- FOLR1-expressing ovarian tumors
Investigates novel therapeutic combinations including targeted therapies and immunotherapy approaches.
Gastrointestinal Oncology
Focuses on treating complex gastrointestinal malignancies including pancreatic ductal adenocarcinoma, cholangiocarcinoma, and gastric cancer.
- Neoadjuvant treatment strategies
- Advanced gastric and gastroesophageal junction cancers
- Pre-operative chemotherapy protocols
Explores innovative combination approaches including chemotherapy and immunotherapy in gastrointestinal cancers.
Precision Oncology
Conducts research in targeted therapies for solid tumors with specific genetic alterations, particularly focusing on KRAS p.G12C mutations and HER2 expression levels.
- Novel drug combinations
- Biomarker-driven treatments
- Advanced breast cancer therapeutics
Evaluates emerging therapeutic approaches in molecularly defined patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.